The Impact of Undertreated Antithrombotic Therapy on Adverse Patient Outcomes
Updated: October 01, 2026
- Antithrombotic therapy is a cornerstone in the approach to reducing the complications of several vascular disorders, including atrial fibrillation (AF), venous thromboembolic disease (VTE), and peripheral vascular disease (PVD). However, balancing the benefits of thrombosis prevention and risks, particularly of medication-related bleeding, is a significant concern for healthcare providers.
- This scientific statement summarizes the current knowledge that antithrombotic undertreatment remains a widespread and clinically significant issue in AF, VTE, and PAD, contributing to preventable morbidity, mortality, and increased health care burden.
- Addressing antithrombotic undertreatment requires sustained system-level change, expansion of antithrombotic stewardship, improved access to therapy, and focused efforts within at-risk populations. As health care teams continue to strengthen interdisciplinary collaboration and integrate evidence-based, stewardship strategies, meaningful progress can be achieved in reducing preventable thrombotic events and improving long-term patient outcomes across AF, VTE, and PAD.
Recommended Reading
- Revisiting the Open Vein Hypothesis to Reduce the Postthrombotic Syndrome: Implications for Multidisciplinary Care and Research
- Understanding the Pain Experience and Treatment Considerations Along the Spectrum of Peripheral Artery Disease
- 2026 Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults
- 2026 Clinical Performance and Quality Measures for Patients With Peripheral Artery Disease
- 2024 Guideline for the Management of Lower Extremity Peripheral Artery Disease